certolizumab - Articles and news items

Golimumab shows higher treatment persistence rates in patients with IMRD

Industry news / 16 February 2016 / Victoria White

A study shows that patients initiating treatment with golimumab had significantly higher persistence rates than those initiating treatment with adalimumab or etanercept at 3 years.


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...